SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based...
Hence then, the article about vivacta bio announces promising first in human results for gt801 an in vivo car t therapy in non hodgkin s lymphoma at the 2025 ash annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting )
Also on site :
- Blizzard conditions and tornadoes disrupt travel as winter brings frigid reality check back to the US
- Arrowhead Stadium Worker Reveals 'Beautifully Kind' Gesture From Taylor Swift During Chiefs' Christmas Day Game
- Samsung Plans to Bring Google Photos to Samsung AI TV Lineup, Helping Users Relive Their Favorite Memories on the Big Screen